Clinical Trial Update: Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HL-085 with vemurafenib in patients with BRAF V600E–mutant non-small cell lung cancer to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HL-085
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN